Zeitschriftenartikel zum Thema „BRAFV600E oncogene“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "BRAFV600E oncogene" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Algazi, Alain Patrick, Megan Othus, Benjamin Newell Voorhies, Kari Lynn Kendra, Shaker R. Dakhil, Amy K. Harker-Murray, Christopher D. Lao et al. „Clinical outcomes in patients with BRAFV600 mutant melanoma and undetectable circulating tumor DNA treated with dabrafenib and trametinib.“ Journal of Clinical Oncology 38, Nr. 15_suppl (20.05.2020): 10059. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.10059.
Der volle Inhalt der QuelleRogounovitch, Tatiana I., Svetlana V. Mankovskaya, Mikhail V. Fridman, Tatiana A. Leonova, Victor A. Kondratovitch, Natalya E. Konoplya, Shunichi Yamashita, Norisato Mitsutake und Vladimir A. Saenko. „Major Oncogenic Drivers and Their Clinicopathological Correlations in Sporadic Childhood Papillary Thyroid Carcinoma in Belarus“. Cancers 13, Nr. 13 (05.07.2021): 3374. http://dx.doi.org/10.3390/cancers13133374.
Der volle Inhalt der QuellePerna, Daniele, Florian A. Karreth, Alistair G. Rust, Pedro A. Perez-Mancera, Mamunur Rashid, Francesco Iorio, Constantine Alifrangis et al. „BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model“. Proceedings of the National Academy of Sciences 112, Nr. 6 (26.01.2015): E536—E545. http://dx.doi.org/10.1073/pnas.1418163112.
Der volle Inhalt der QuelleKaabouch, Meryem, Hafsa Chahdi, Naima Azouzi, Mohammed Oukabli, Issam Rharrassi, Adil Boudhas, Hassan Jaddi et al. „BRAFV600E hot spot mutation in thyroid carcinomas: first Moroccan experience from a single-institution retrospective study“. African Health Sciences 20, Nr. 4 (16.12.2020): 1849–56. http://dx.doi.org/10.4314/ahs.v20i4.40.
Der volle Inhalt der QuelleWang, Liye, Qianyi Lu, Kuikui Jiang, Ruoxi Hong, Shusen Wang und Fei Xu. „BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review“. Oncology Research and Treatment 45, Nr. 1-2 (24.11.2021): 54–61. http://dx.doi.org/10.1159/000520453.
Der volle Inhalt der QuelleZurnadzhy, Liudmyla, Tetiana Bogdanova, Tatiana I. Rogounovitch, Masahiro Ito, Mykola Tronko, Shunichi Yamashita, Norisato Mitsutake, Serhii Chernyshov, Sergii Masiuk und Vladimir A. Saenko. „The BRAFV600E Mutation Is Not a Risk Factor for More Aggressive Tumor Behavior in Radiogenic and Sporadic Papillary Thyroid Carcinoma at a Young Age“. Cancers 13, Nr. 23 (30.11.2021): 6038. http://dx.doi.org/10.3390/cancers13236038.
Der volle Inhalt der QuelleHosier, Gregory W., und Matthew T. Roberts. „Initial response of renal cell carcinoma to vemurafenib in a patient treated for metastatic melanoma“. Canadian Urological Association Journal 10, Nr. 9-10 (13.09.2016): 306. http://dx.doi.org/10.5489/cuaj.3652.
Der volle Inhalt der QuelleChabanet, Tamer Basel, Shannon Steinberg, Peisheng Zhang und Mary Jo Turk. „Elucidating the oncogene-driven regulatory T cell responses during melanoma tumorigenesis.“ Journal of Immunology 196, Nr. 1_Supplement (01.05.2016): 74.1. http://dx.doi.org/10.4049/jimmunol.196.supp.74.1.
Der volle Inhalt der QuelleKidger, Andrew M., Linda K. Rushworth, Julia Stellzig, Jane Davidson, Christopher J. Bryant, Cassidy Bayley, Edward Caddye, Tim Rogers, Stephen M. Keyse und Christopher J. Caunt. „Dual-specificity phosphatase 5 controls the localized inhibition, propagation, and transforming potential of ERK signaling“. Proceedings of the National Academy of Sciences 114, Nr. 3 (04.01.2017): E317—E326. http://dx.doi.org/10.1073/pnas.1614684114.
Der volle Inhalt der QuelleSpourquet, Catherine, Ophélie Delcorte, Pascale Lemoine, Nicolas Dauguet, Axelle Loriot, Younes Achouri, Maija Hollmén et al. „BRAFV600E Expression in Thyrocytes Causes Recruitment of Immunosuppressive STABILIN-1 Macrophages“. Cancers 14, Nr. 19 (26.09.2022): 4687. http://dx.doi.org/10.3390/cancers14194687.
Der volle Inhalt der QuelleLee, Min Hee, Seong Eun Lee, Dong Wook Kim, Min Jeong Ryu, Sung Jin Kim, Sung Joong Kim, Yong Kyoung Kim et al. „Mitochondrial Localization and Regulation of BRAFV600E in Thyroid Cancer: A Clinically Used RAF Inhibitor Is Unable to Block the Mitochondrial Activities of BRAFV600E“. Journal of Clinical Endocrinology & Metabolism 96, Nr. 1 (01.01.2011): E19—E30. http://dx.doi.org/10.1210/jc.2010-1071.
Der volle Inhalt der Quellevon Soosten, Laura, Janina Haar, Veronika Frehtman, Stefan Holderbach, Julius Upmeier zu Belzen, Michael Jendrusch, Konstantin Okonechnikov et al. „THER-01. Precision brain tumor therapy by AAV-mediated oncogene editing“. Neuro-Oncology 24, Supplement_1 (01.06.2022): i185—i186. http://dx.doi.org/10.1093/neuonc/noac079.695.
Der volle Inhalt der QuelleAdamopoulos, Christos, Kostas A. Papavassiliou, Poulikos I. Poulikakos und Athanasios G. Papavassiliou. „RAF and MEK Inhibitors in Non-Small Cell Lung Cancer“. International Journal of Molecular Sciences 25, Nr. 9 (24.04.2024): 4633. http://dx.doi.org/10.3390/ijms25094633.
Der volle Inhalt der QuelleBaldari, Silvia, Giuliana Di Rocco, Marie C. Heffern, Timothy A. Su, Christopher J. Chang und Gabriele Toietta. „Effects of Copper Chelation on BRAFV600E Positive Colon Carcinoma Cells“. Cancers 11, Nr. 5 (12.05.2019): 659. http://dx.doi.org/10.3390/cancers11050659.
Der volle Inhalt der QuelleJiang, Cuiping, Lin Xie, Yiding Zhang, Masayuki Fujinaga, Wakana Mori, Yusuke Kurihara, Tomoteru Yamasaki, Feng Wang und Ming-Rong Zhang. „Pharmacokinetic Evaluation of [11C]CEP-32496 in Nude Mice Bearing BRAFV600E Mutation-Induced Melanomas“. Molecular Imaging 17 (01.01.2018): 153601211879595. http://dx.doi.org/10.1177/1536012118795952.
Der volle Inhalt der QuelleRiesco-Eizaguirre, G., P. Gutiérrez-Martínez, M. A. García-Cabezas, M. Nistal und P. Santisteban. „The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane“. Endocrine-Related Cancer 13, Nr. 1 (März 2006): 257–69. http://dx.doi.org/10.1677/erc.1.01119.
Der volle Inhalt der QuelleRecagni, Tassinari, Doria, Cimino-Reale, Zaffaroni, Freccero, Folini und Richter. „The Oncogenic Signaling Pathways in BRAF-Mutant Melanoma Cells are Modulated by Naphthalene Diimide-Like G-Quadruplex Ligands“. Cells 8, Nr. 10 (18.10.2019): 1274. http://dx.doi.org/10.3390/cells8101274.
Der volle Inhalt der QuelleUribe-Alvarez, Cristina, Daniela Araiza-Olivera, Alexa Cannon und Jonathan Chernoff. „Abstract 4747: Novel targets for BRAFV600E and BRAFV600ERAC1P29S drug resistant melanoma“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 4747. http://dx.doi.org/10.1158/1538-7445.am2024-4747.
Der volle Inhalt der QuelleWongchenko, Matthew J., Antoni Ribas, Paolo A. Ascierto, Brigitte Dréno, Anna Maria di Giacomo, Claus Garbe, Ilsung Chang et al. „Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study“. JCO Precision Oncology, Nr. 2 (November 2018): 1–18. http://dx.doi.org/10.1200/po.17.00242.
Der volle Inhalt der QuelleChaft, Jamie E., Scott Swanson, Jay M. Lee, Jules Lin, Hisashi Tsukada, Tianhong Li, R. Taylor Ripley et al. „Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early stage lung cancer (LEADER) screening trial.“ Journal of Clinical Oncology 42, Nr. 16_suppl (01.06.2024): 8068. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.8068.
Der volle Inhalt der QuelleTosios, Konstantinos I., Eleni-Marina Kalogirou und Ioannis G. Koutlas. „Association of MDM2 Overexpression in Ameloblastomas with MDM2 Amplification and BRAFV600E Expression“. International Journal of Molecular Sciences 25, Nr. 4 (13.02.2024): 2238. http://dx.doi.org/10.3390/ijms25042238.
Der volle Inhalt der QuelleStocksdale, Brian, Yaping Joyce Liao, Gwen Coffey und Seema Nagpal. „INNV-06. SECOND GENERATION BRAF/MEK INHIBITION IN ANAPLASTIC PLEOMORPHIC XANTHROASTROCYTOMA“. Neuro-Oncology 22, Supplement_2 (November 2020): ii117—ii118. http://dx.doi.org/10.1093/neuonc/noaa215.490.
Der volle Inhalt der QuelleDimitrion, Peter, Jugmohit Toor, James Ge, Qiyan Wang, Carl E. Allen, Li Zhou und Qing-Sheng Mi. „HDAC3 Is Required for Pathognomonic Features of Langerhans Cell Histiocytes“. Blood 142, Supplement 1 (28.11.2023): 676. http://dx.doi.org/10.1182/blood-2023-185195.
Der volle Inhalt der QuelleCangi, Maria Giulia, Riccardo Biavasco, Giulio Cavalli, Greta Grassini, Elena Dal-Cin, Corrado Campochiaro, Barbara Guglielmi et al. „BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease“. Annals of the Rheumatic Diseases 74, Nr. 8 (26.03.2014): 1596–602. http://dx.doi.org/10.1136/annrheumdis-2013-204924.
Der volle Inhalt der QuelleHassan, Alaa A., Nasr K. Mohamed, Ashraf A. Aly, Mohamed Ramadan, Hesham A. M. Gomaa, Ahmed T. Abdel-Aziz, Bahaa G. M. Youssif, Stefan Bräse und Olaf Fuhr. „Synthesis and Antiproliferative Potential of Thiazole and 4-Thiazolidinone Containing Motifs as Dual Inhibitors of EGFR and BRAFV600E“. Molecules 28, Nr. 24 (05.12.2023): 7951. http://dx.doi.org/10.3390/molecules28247951.
Der volle Inhalt der QuelleSigaud, Romain, Florian Selt, Thomas Hielscher, Nina Overbeck, Diren Usta, Marc Remke, Daniel Picard et al. „LGG-14. MULTI-OMIC ANALYSIS OF MAPK ACTIVATION IN PEDIATRIC PILOCYTIC ASTROCYTOMA“. Neuro-Oncology 22, Supplement_3 (01.12.2020): iii368. http://dx.doi.org/10.1093/neuonc/noaa222.396.
Der volle Inhalt der QuelleGrob, Sydney, Lianna Nobre, Kurtis Davies, Scott Ryall, Dara Aisner, Lindsey Hoffman, Shadi Zahedi et al. „LGG-34. CLINICAL AND MOLECULAR CHARACTERIZATION OF A MULTI-INSTITUTIONAL COHORT OF PEDIATRIC SPINAL CORD LOW-GRADE GLIOMAS“. Neuro-Oncology 22, Supplement_3 (01.12.2020): iii373. http://dx.doi.org/10.1093/neuonc/noaa222.416.
Der volle Inhalt der QuelleSadangi, Shreyans, Katarina Milosavljevic, Edgardo Castro-Perez, Marcos Lares, Mithalesh Singh, Sarah Altameemi, David J. Beebe, Jose M. Ayuso und Vijayasaradhi Setaluri. „Role of the Skin Microenvironment in Melanomagenesis: Epidermal Keratinocytes and Dermal Fibroblasts Promote BRAF Oncogene-Induced Senescence Escape in Melanocytes“. Cancers 14, Nr. 5 (27.02.2022): 1233. http://dx.doi.org/10.3390/cancers14051233.
Der volle Inhalt der QuelleAlaali, Lujain A., Ming Yuan, Chales Eberhart und Eric Raabe. „Abstract 3414: The pan-RAF inhibitor tovorafenib suppresses NF1-mutant glioma through upregulation of FOXO1 and triggering of oncogene-induced senescence“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 3414. http://dx.doi.org/10.1158/1538-7445.am2023-3414.
Der volle Inhalt der QuelleAlaali, Lujain, Eric Raabe, Micah Maxwell, Charles Eberhart und Hui Zhang. „DDDR-18. COMPREHENSIVE PROTEOMIC PROFILING OF BRAFV600E GLIOMA CELLS SHOWS UPREGULATION OF GLYCOLYSIS AND TCA CYCLE PROTEINS AFTER COMBINED MTOR AND MAP KINASE PATHWAY BLOCKADE“. Neuro-Oncology 24, Supplement_7 (01.11.2022): vii102. http://dx.doi.org/10.1093/neuonc/noac209.383.
Der volle Inhalt der QuelleTemprine, Kelsey, Nathaniel R. Campbell, Richard Huang, Erin M. Langdon, Theresa Simon-Vermot, Krisha Mehta, Averill Clapp, Mollie Chipman und Richard M. White. „Regulation of the error-prone DNA polymerase Polκ by oncogenic signaling and its contribution to drug resistance“. Science Signaling 13, Nr. 629 (28.04.2020): eaau1453. http://dx.doi.org/10.1126/scisignal.aau1453.
Der volle Inhalt der QuelleSong, Kai, Jenna K. Minami, Arthur Huang, Siavash R. Dehkordi, Shirley H. Lomeli, Jens Luebeck, Mark H. Goodman et al. „Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges“. Cancer Discovery 12, Nr. 4 (20.12.2021): 1046–69. http://dx.doi.org/10.1158/2159-8290.cd-20-0936.
Der volle Inhalt der QuelleCorso, Giovanni, Valeria Pascale, Giuseppe Flauti, Daniele Marrelli und Franco Roviello. „Oncogenic mutations in colorectal cancer, indications for anatomical sites, and targeted intervention.“ Journal of Clinical Oncology 31, Nr. 15_suppl (20.05.2013): e22037-e22037. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e22037.
Der volle Inhalt der QuelleNgiow, Shin Foong, Katrina M. Meeth, Kimberley Stannard, Deborah S. Barkauskas, Gideon Bollag, Marcus Bosenberg und Mark J. Smyth. „Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma“. OncoImmunology 5, Nr. 3 (10.12.2015): e1089381. http://dx.doi.org/10.1080/2162402x.2015.1089381.
Der volle Inhalt der QuelleLuciano, Angelo, Luigi Liguori, Giovanna Polcaro, Francesco Sabbatino und Stefano Pepe. „Evaluation of Potential Predictive Biomarkers for Defining Brain Radiotherapy Efficacy in Non-Small Cell Lung Cancer Patients with Brain Metastases: A Case Report and a Narrative Review“. Clinics and Practice 13, Nr. 6 (30.11.2023): 1549–60. http://dx.doi.org/10.3390/clinpract13060136.
Der volle Inhalt der QuelleDrilon, Alexander E., Melissa Lynne Johnson, Shirish M. Gadgeel, Dale Nepert, Gang Feng, Marzieh Golmakani, Micaela Reddy et al. „A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.“ Journal of Clinical Oncology 41, Nr. 16_suppl (01.06.2023): 3020. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3020.
Der volle Inhalt der QuelleRobb, Ryan, Linlin Yang, Changxian Shen, Adam R. Wolfe, Amy Webb, Xiaoli Zhang, Marall Vedaie et al. „Inhibiting BRAF Oncogene–Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair“. Clinical Cancer Research 25, Nr. 15 (16.05.2019): 4749–60. http://dx.doi.org/10.1158/1078-0432.ccr-18-3625.
Der volle Inhalt der QuelleAlotaibi, Sultan, Osama Alhafi, Hatem Nasr, Khalid Eltayeb und Ghaleb Elyamany. „Erdheim-Chester Disease: Case Report with Aggressive Multisystem Manifestations and Review of the Literature“. Case Reports in Oncology 10, Nr. 2 (14.06.2017): 501–7. http://dx.doi.org/10.1159/000477336.
Der volle Inhalt der QuelleDawar, Richa, Kunal Gawri, Estelamari Rodriguez, Deukwoo Kwon, Fahmin Basher, Philippos Apolinario Costa, Khadeja Khan, Tisdrey Torres, Chukwuemeka Ikpeazu und Gilberto Lopes. „Clinical attributes and outcomes in metastatic non-small cell lung cancer bearing BRAF mutations treated with targeted therapy versus immunotherapy.“ Journal of Clinical Oncology 39, Nr. 15_suppl (20.05.2021): e21219-e21219. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e21219.
Der volle Inhalt der QuelleGeisen, Mariah, Josiane weber-Tessmann, Courtney Kelson, Daheng He, Chi Wang, Abu Saleh Mosa Faisal, Jill Kolesar und Yekaterina Zaytseva. „Abstract 4760: Inhibition of FASN postpones development of resistance to BRAF inhibitors in colorectal cancer“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 4760. http://dx.doi.org/10.1158/1538-7445.am2024-4760.
Der volle Inhalt der QuelleRiesco-Eizaguirre, Garcilaso, Irene Rodríguez, Antonio De la Vieja, Eugenia Costamagna, Nancy Carrasco, Manuel Nistal und Pilar Santisteban. „The BRAFV600E Oncogene Induces Transforming Growth Factor β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer“. Cancer Research 69, Nr. 21 (27.10.2009): 8317–25. http://dx.doi.org/10.1158/0008-5472.can-09-1248.
Der volle Inhalt der QuelleSchott, M. „The BRAFV600E Oncogene Induces Transforming Growth Factor β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer“. Yearbook of Endocrinology 2010 (Januar 2010): 154–55. http://dx.doi.org/10.1016/s0084-3741(10)79511-1.
Der volle Inhalt der QuellePricl, Sabrina, Erik Laurini, Domenico Marson und Gabriele Cavalieri. „Abstract C153: Rare BRAF mutations in menlanoma and beyond: Rationalizing the afficacy of B-raf inhibitors via HPC-based in silico/in vitro investigations“. Molecular Cancer Therapeutics 22, Nr. 12_Supplement (01.12.2023): C153. http://dx.doi.org/10.1158/1535-7163.targ-23-c153.
Der volle Inhalt der QuelleLim, Kee Siang, Zachary Wei Ern Yong, Huajing Wang, Tuan Zea Tan, Ruby Yun-Ju Huang, Daisuke Yamamoto, Noriyuki Inaki et al. „Inflammatory and mitogenic signals drive interleukin 23 subunit alpha (IL23A) secretion independent of IL12B in intestinal epithelial cells“. Journal of Biological Chemistry 295, Nr. 19 (24.03.2020): 6387–400. http://dx.doi.org/10.1074/jbc.ra120.012943.
Der volle Inhalt der QuelleChan, Lai N., Christian Hurtz, Huimin Geng, Franziska Auer, Zhengshan Chen, Gang Xiao, Jae-Woong Lee, Kadriye Nehir Cosgun, B. Hilda Ye und Markus Muschen. „Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor Signaling“. Blood 132, Supplement 1 (29.11.2018): 1336. http://dx.doi.org/10.1182/blood-2018-99-115514.
Der volle Inhalt der QuelleLiebig, Janika K., Silke Kuphal und Anja Katrin Bosserhoff. „HuRdling Senescence: HuR Breaks BRAF-Induced Senescence in Melanocytes and Supports Melanoma Growth“. Cancers 12, Nr. 5 (21.05.2020): 1299. http://dx.doi.org/10.3390/cancers12051299.
Der volle Inhalt der QuelleKunz, Manfred, und Julio Vera. „Modelling of Protein Kinase Signaling Pathways in Melanoma and Other Cancers“. Cancers 11, Nr. 4 (03.04.2019): 465. http://dx.doi.org/10.3390/cancers11040465.
Der volle Inhalt der QuelleGroisberg, Roman, David S. Hong, Filip Janku, Yunfang Jiang, ChongJuan Wei, Daniel D. Karp, Apostolia Maria Tsimberidou et al. „SWI/SNF complex subunit aberrations in diverse cancers: Next-generation sequencing of 539 patients.“ Journal of Clinical Oncology 35, Nr. 15_suppl (20.05.2017): 2588. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.2588.
Der volle Inhalt der QuelleBorgenvik, Anna, Sean Misek, Alexander Zhang, Ruth Fekade, Timothy Ragnoni, Aaron Fultineer, Kevin Zhou et al. „LGG-29. BEYOND MAPK SIGNALING - GENOME-SCALE CRISPR/CAS9 SCREENS REVEAL NEW TARGETS FOR TREATMENT OF KIAA1549::BRAF-DRIVEN PEDIATRIC LOW-GRADE GLIOMA“. Neuro-Oncology 26, Supplement_4 (18.06.2024): 0. http://dx.doi.org/10.1093/neuonc/noae064.422.
Der volle Inhalt der QuelleLee, Joon-Hyop, Jiyoung Ahn, Won Seo Park, Eun Kyung Choe, Eunyoung Kim, Rumi Shin, Seung Chul Heo et al. „Colorectal Cancer Prognosis is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study“. Journal of Clinical Medicine 8, Nr. 1 (17.01.2019): 111. http://dx.doi.org/10.3390/jcm8010111.
Der volle Inhalt der Quelle